ArticleLancet (London, England)2020

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.

Feng-Cai Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.